Compare AstraZeneca plc (AZN) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Kaltura Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Kaltura Inc trades at $1.64 (market cap $249.42M). The key difference: AstraZeneca plc is far larger — about 994.9× Kaltura Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| AZN | KLTR | |
|---|---|---|
Market Cap | $248.14B | $249.42M |
Sector | Health | Technology |
52-Week High | $209.48 | $1.89 |
52-Week Low | $147.06 | $1.08 |
Enterprise Value | $275.41B | $261.64M |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
KLTR trades at $1.59, down 3.05% today, with a bullish technical signal from moving averages and strong institutional recognition for its AI-driven digital experience platform. Revenue is stable around $181M annually, but the company remains unprofitable, with a net income margin of -6.92% in 2026. Recent earnings beats and multiple industry awards highlight operational progress amid high valuation multiples like EV/EBITDA of 336.29.
The outlook is cautiously optimistic due to consistent revenue and margin improvements, but persistent losses and high debt pose risks. Analyst sentiment is mixed with a 44.45% buy rating, suggesting potential upside if profitability is achieved, though investor caution is warranted given the negative cash flow and insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
